Want to see IN:HESTERBIO full AI Analyst Report?
HESTERBIO Stock Chart & Stats
₹1605.75
-₹5.75(-0.24%)
At close: 4:00 PM EST
₹1605.75
-₹5.75(-0.24%)
Day’s Range― - ―
52-Week Range₹1,250.95 - ₹2,531.25
Previous CloseN/A
Volume2.45K
Average Volume (3M)308.00
Market Cap
₹17.94B
Enterprise Value₹19.38B
Total Cash (Recent Filing)₹65.38M
Total Debt (Recent Filing)₹1.95B
Price to Earnings (P/E)38.0
Beta0.54
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.44%
Share Statistics
EPS (TTM)66.93
Shares Outstanding8,506,865
10 Day Avg. Volume428
30 Day Avg. Volume308
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.88
Price to Sales (P/S)3.12
P/FCF Ratio24.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Steady Multi-year Revenue Growth And 2026 Re-accelerationConsistent multi-year revenue expansion and a clear 2026 re-acceleration indicate durable demand for veterinary vaccines and products. This supports predictable recurring sales, better capacity utilization and long-term scaling of manufacturing and distribution investments.
Improving Leverage And Stronger Returns On EquityMaterial reduction in leverage and rising ROE reflect strengthening financial resilience. Lower leverage increases strategic optionality for capex, R&D or M&A, while better returns show management is allocating capital more effectively over a multi-year horizon.
Recovery To Positive And Meaningful Free Cash FlowReturn to positive free cash flow and substantial cash conversion in 2026 shows earnings are translating into real cash available for reinvestment or deleveraging. Sustained FCF supports durable financing of working capital and product pipeline without reliance on external funding.
Bears Say
Historic Margin Volatility And Uneven Earnings QualitySignificant swings in gross and net margins reduce predictability of profitability and complicate financial planning. Persistent margin variability can undermine long-term margin sustainability, making capital allocation, pricing power and investor forecasting more uncertain.
Past Negative Free Cash Flow And Inconsistent OCF Coverage Of DebtEpisodes of deeply negative free cash flow and weak operating cash coverage of debt signal execution and liquidity risk. If cash conversion weakens again, the firm may face tougher choices between capex, R&D, dividend policy or external financing over the medium term.
Absolute Debt Remains Sizable Despite ImprovementEven with falling leverage ratios, a sizable absolute debt load limits financial flexibility and increases exposure to interest-cost or demand shocks. The company remains more vulnerable to profit softness or higher rates than peers with minimal debt.
Hester Biosciences Limited News
HESTERBIO FAQ
What was Hester Biosciences Limited’s price range in the past 12 months?
Hester Biosciences Limited lowest stock price was ₹1250.95 and its highest was ₹2531.25 in the past 12 months.
What is Hester Biosciences Limited’s market cap?
Hester Biosciences Limited’s market cap is ₹17.94B.
When is Hester Biosciences Limited’s upcoming earnings report date?
Hester Biosciences Limited’s upcoming earnings report date is Aug 12, 2026 which is in 28 days.
How were Hester Biosciences Limited’s earnings last quarter?
Hester Biosciences Limited released its earnings results on May 15, 2026. The company reported ₹18.787 earnings per share for the quarter, beating the consensus estimate of N/A by ₹18.787.
Is Hester Biosciences Limited overvalued?
According to Wall Street analysts Hester Biosciences Limited’s price is currently Overvalued.
Does Hester Biosciences Limited pay dividends?
Hester Biosciences Limited pays a Annually dividend of ₹11 which represents an annual dividend yield of 0.44%. See more information on Hester Biosciences Limited dividends here
What is Hester Biosciences Limited’s EPS estimate?
Hester Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hester Biosciences Limited have?
Hester Biosciences Limited has 8,506,865 shares outstanding.
What happened to Hester Biosciences Limited’s price movement after its last earnings report?
Hester Biosciences Limited reported an EPS of ₹18.787 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.669%.
Which hedge fund is a major shareholder of Hester Biosciences Limited?
Currently, no hedge funds are holding shares in IN:HESTERBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hester Biosciences Limited
Hester Biosciences Limited, founded in 1987 and headquartered in Ahmedabad, India, specializes in the production and commercialization of veterinary vaccines and a comprehensive array of animal health solutions. The company's operations span both domestic and international markets, structured around two primary divisions: Poultry Healthcare and Animal Healthcare. Its extensive range of poultry vaccines targets numerous conditions, including Newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, egg drop syndrome, reovirus infections, Marek's disease, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, and avian encephalomyelitis. For larger animals, Hester Biosciences provides vaccines designed to combat ailments such as Goat Pox, Peste des Petits Ruminants (PPR), Brucellosis, Mastitis, Metritis, various infectious diseases, reproductive disorders, theileriosis, and parasitic infestations. Beyond vaccines, the company's product portfolio encompasses vital feed supplements like toxin binders, trace minerals, enzyme preparations, and bypass fats. It also supplies disinfectants for maintaining farm hygiene and sanitizing equipment, along with water purification solutions. Nutritional support products are offered, including mineral mixtures, fertility boosters, and growth tonics. A significant portion of their offerings consists of herbal preparations, featuring growth promoters, natural alternatives to choline chloride, stress and immunity enhancers, respiratory aids, liver tonics, wound healing agents, uterine and digestive tonics, anti-bloat remedies, ectoparasiticides, and treatments for anti-mastitis and anti-prolapse conditions.
Technical Analysis
Gufic Biosciences Limited
―
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
―
Unichem Laboratories Limited
―







